Abstract
Non-amyloidogenic α-secretase processing of amyloid precursor protein (APP) is stimulated by protein kinase C (PKC). Levels and activity of PKC are decreased in sporadic Alzheimer's disease skin fibroblasts. We investigated whether alterations in PKC and PKC-mediated APP processing occur also in fibroblasts established from individuals with familial Alzheimer's disease APP KM670/671NL, PS1 M146V and H163Y mutations. These pathogenic mutations are known to alter APP metabolism to increase Aβ. PKC activities, but not levels, were decreased by 50% in soluble fractions from sporadic Alzheimer's disease cases. In contrast, familial Alzheimer's disease fibroblasts showed no significant changes in PKC enzyme activity. Fibroblasts bearing the APP KM670/671NL mutation showed no significant differences in either PKC levels or PKC-mediated soluble APP (APPs) secretion, compared to controls. Fibroblasts bearing PS1 M146V and H163Y mutations showed a 30% increase in soluble PKC levels and a 40% decrease in PKC-mediated APPs secretion. These results indicate that PKC deficits are unlikely to contribute to increased Aβ seen with APP and PS1 mutations, and also that PS1 mutations decrease α-secretase derived APPs production independently of altered PKC activity. Copyright (C) 1999 Elsevier Science B.V.
Original language | British English |
---|---|
Pages (from-to) | 341-350 |
Number of pages | 10 |
Journal | Biochimica et Biophysica Acta - Molecular Basis of Disease |
Volume | 1453 |
Issue number | 3 |
DOIs | |
State | Published - 30 Mar 1999 |
Keywords
- Alzheimer's disease
- Amyloid precursor protein
- Fibroblast
- Presenilin
- Protein kinase C